Cart
sales@molnova.com
Ulixertinib
CAS No. 869886-67-9
Ulixertinib( BVD-523 | VRT752271 )
Catalog No. M17630 CAS No. 869886-67-9
Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 80 | In Stock |
|
| 25MG | 129 | In Stock |
|
| 50MG | 177 | In Stock |
|
| 100MG | 335 | In Stock |
|
| 200MG | 484 | In Stock |
|
| 500MG | 771 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUlixertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionUlixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
-
DescriptionUlixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
-
In Vitro——
-
In Vivo——
-
SynonymsBVD-523 | VRT752271
-
PathwayOthers
-
TargetOther Targets
-
RecptorERK2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number869886-67-9
-
Formula Weight433.33
-
Molecular FormulaC21H22Cl2N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 45 mg/mL; 103.85 mM
-
SMILES[nH]1c(cc(c1)c1cc(ncc1Cl)NC(C)C)C(=O)N[C@H](CO)c1cc(ccc1)Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ward RA, et al. J Med Chem. 2015, 58(11), 4790-4801.
molnova catalog
related products
-
Tegadifur
Tegadifur (40497S) is an orally available antitumor compound with antimetabolic effects, often used with uracil and in the treatment of rectal adenocarcinoma.
-
Longikaurin E
Longikaurin E is a therapeutic agent for pancreatic cancer. It is isolated from Isodon adenolomus.
-
4-Hydroxybenzyl alco...
4-Hydroxybenzyl alcohol exhibits beneficial effects in cerebral ischemic injury, has neuroprotective effect through upregulation of Nrf2, Prdx6, and PDI expression via the PI3K/Akt pathway.
